Question Bank › Borrowed urgency: counterparties are racing the

Borrowed urgency: counterparties are racing the company's clock, not their own

Calls Tested
499
Answered YES
7
Hit Rate
1.4%
rare by design

MannKind Corporation (MNKD) — this company's answers

NO on the Q4 2023 call 2024-02-27 C
The model's full reasoning — Q4 2023 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management describes counterparties adjusting timing/plans around company's schedule/availability, real current, not hope. Need only transcript. Let's parse. Company MannKind. Products: Tyvaso DPI manufacturing for United Therapeutics, Afrezza, V-Go, pipeline. Need see if any counterparties (United Therapeutics? patients? partners?) are adjusting their own timing around company's schedule/availability. Management mentions Tyvaso DPI record production, UT. But no explicit "UT is adjusting timing around us." They mention high-speed fill finish line qualification, PPQ. Not counterparty. Maybe "we have 100 sites target... no other option for patients to enroll besides current drug" not. Question asks: "On this call, does management describe that the company's CUSTOMERS, PARTNERS, OR OTHER COUNTERPARTIES ARE NOW ADJUSTING THEIR OWN TIMING, PLANS, OR BEHAVIOR AROUND THE COMPANY'S SCHEDULE OR AVAILABILITY — that is, the other side is visibly reorganizing when and how it acts in order to be ready for, to secure, or to keep pace with what this company is doing — and does management present this as something actually happening in current dealings rather than as a hope or a projection?" Need find evidence. Let's read transcript carefully. Michael: "We will make over 25 million doses and devices in 2024 and helped roughly 25,000 patients take a MannKind-produced product in 2023, the most in our history. In Q4, we had record revenue for Tyvaso on both royalty and collaboration manufacturing, along with record production on Tyvaso cartridges." No. "Many of you asked, could we have sold more? Why didn't we sell more? ... We're very excited about Tyvaso DPI ... anticipate hopefully positive milestones for Tyvaso in the future and, therefore, want to preserve 90% of that value for our shareholders." No. "At the same time, we want to deep risk on the debt side... restructured insulin purchase commitment and reduced near-term cash outlay by $50 million." No. "Afrezza net revenue grew $12 million, or 27% year-over-year. This is our largest jump in seven years and is the most we've seen driven by volume alone as opposed to price balance by historical standards." No. "Several clinical readouts in 2024 may expand our market potential" No.

← Back to the full MNKD analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's CUSTOMERS, PARTNERS, OR OTHER COUNTERPARTIES ARE NOW ADJUSTING THEIR OWN TIMING, PLANS, OR BEHAVIOR AROUND THE COMPANY'S SCHEDULE OR AVAILABILITY — that is, the other side is visibly reorganizing when and how it acts in order to be ready for, to secure, or to keep pace with what this company is doing — and does management present this as something actually happening in current dealings rather than as a hope or a projection? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon: the direction of accommodation has flipped, and counterparties are now bending to the company's clock. Any genuine expression of this counts, and the form varies widely across industries. For example — customers placing orders, signing, or committing earlier than their own normal cycle because of when the company's product, capacity, slots, or availability will exist; buyers reserving, prepaying, depositing, or locking in now specifically to hold a place against the company's future output or calendar; counterparties accelerating their own projects, build-outs, launches, or internal approvals so they are ready when the company is; customers asking the company to slow down, phase, or sequence deliveries because they cannot absorb what is coming as fast as it is arriving; partners or channels rearranging their own rollouts, seasons, or plans around the company's timing; counterparties accepting the company's lead times, windows, or schedule as the constraint they must plan around rather than dictating their own; or management describing that conversations now revolve around the company's availability and calendar rather than the counterparty's preferences. Two things should come through in management's own voice. First, the adjustment must be REAL AND CURRENT — described as observable behavior in recent or ongoing dealings (orders placed early, commitments made ahead of need, plans shifted, readiness work on the counterparty's side), not as something management expects, hopes, or believes should happen. Second, the adjustment must be AROUND THE COMPANY — the counterparty is timing itself to this company's schedule, availability, or output, not merely acting quickly for its own unrelated reasons, and not simply buying more in the ordinary course. Answer NO if management simply reports strong demand, a good quarter, a healthy pipeline, or fast-growing orders in the usual way, with no sense that counterparties are changing their own timing or plans around the company. NO if the urgency described belongs to the company itself (management racing to execute) rather than to the other side. NO if earlier buying is attributed by management chiefly to a temporary shortage, a pre-buy ahead of a price increase, a regulatory deadline, seasonality, or stockpiling that management expects to unwind. NO if the only evidence is one isolated deal or anecdote with no sense of a broader pattern. NO if the behavior is only anticipated, hoped for, or described as something the company is working to create. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
PDS Precision Drilling Corporation Q1 2024 2024-04-25 B
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
HY Hyster-Yale Materials Handling, Inc. Q3 2021 2021-11-06 D
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
FSS Federal Signal Corporation Q1 2018 2018-05-12 A

How the model reasoned

PDS · Q1 2024 → YESThe question is: Does management describe that the company's CUSTOMERS, PARTNERS, OR OTHER COUNTERPARTIES ARE NOW ADJUSTING THEIR OWN TIMING, PLANS, OR BEHAVIOR AROUND THE COMPANY'S SCHEDULE OR AVAILA...
TACT · Q4 2022 → YESThe question is: Does management describe that the company's CUSTOMERS, PARTNERS, OR OTHER COUNTERPARTIES ARE NOW ADJUSTING THEIR OWN TIMING, PLANS, OR BEHAVIOR AROUND THE COMPANY'S SCHEDULE OR AVAILA...
CRL · Q2 2022 → YESThe question is: Does management describe that the company's CUSTOMERS, PARTNERS, OR OTHER COUNTERPARTIES ARE NOW ADJUSTING THEIR OWN TIMING, PLANS, OR BEHAVIOR AROUND THE COMPANY'S SCHEDULE OR AVAILA...

More from the question bank

Earned recurrence: demand arriving from firsStory upgraded mid-callDeprived of a working part of itselfLiving hand-to-mouth on their own outputBuyers widening their own doorsConversation has moved to deliveryAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.